LEF1

Across TCGA pan-cancer cohorts, LEF1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LEF1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LEF1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LEF1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where LEF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.269	0.597	.003	24	view →
HNSC	DFS	Median	All	1.000	0.378	.019	8	view →
LUAD	DFS	Quartile	II,III,IV	0.771	0.271	.016	6	view →
LSCC	DFS	Quartile	All	0.244	0.849	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LEF1–PDAC (DFS)

Open the PDAC breakdown →